Ok thanks. The updated results will carry a lot of weight.
The first round of results didn’t meet the primary objective of PFS but the secondary objectives of OS shows a significant improvement and quality of life is improved.
I’m wondering why all the analyst reports keep talking about an AIPAC ph3. The company hasn’t made any announcement about this, unless I missed something.
Also, if the AIPAC ph2b was enough for EMA registration
why is there even talk of a ph3?
is it that results aren’t quite good enough to justify the risk of a therapy not fully tested?. The recent results in other Efti trials will help. We wait in hope of the updated AIPAC results getting us over the line.
- Forums
- ASX - By Stock
- IMM
- News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc
News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc, page-18
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
35.5¢ |
Change
0.060(20.3%) |
Mkt cap ! $515.6M |
Open | High | Low | Value | Volume |
36.0¢ | 37.5¢ | 33.5¢ | $6.427M | 18.03M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 35.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
36.0¢ | 133736 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 0.355 |
2 | 9500 | 0.350 |
4 | 199315 | 0.345 |
10 | 84868 | 0.340 |
2 | 10985 | 0.335 |
Price($) | Vol. | No. |
---|---|---|
0.360 | 96182 | 4 |
0.365 | 81517 | 4 |
0.370 | 150545 | 8 |
0.375 | 156434 | 4 |
0.380 | 167642 | 11 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |